Biomarin Pharmaceutical (BMRN) Non-Current Deffered Revenue (2010 - 2012)

Biomarin Pharmaceutical (BMRN) has 3 years of Non-Current Deffered Revenue data on file, last reported at $13.1 million in Q3 2012.

• Quarterly Non-Current Deffered Revenue rose 1222.66% year-over-year to $13.1 million in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $13.1 million (up 1222.66% YoY) and the FY2011 annual result came in at $950000.0, down 81.78% from the prior year.
• Non-Current Deffered Revenue climbed to $13.1 million in Q3 2012, from $12.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $13.1 million in Q3 2012 to a low of $950000.0 in Q4 2011.
• A 3-year average of $6.1 million and a median of $5.2 million in 2010 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2011 — Non-Current Deffered Revenue tumbled 81.78% — and 2012, when it soared 1222.66%.
• Tracing BMRN's Non-Current Deffered Revenue over 3 years: stood at $5.2 million in 2010, then plunged by 81.78% to $950000.0 in 2011, then surged by 1282.53% to $13.1 million in 2012.
• The last three Non-Current Deffered Revenue figures came in at $13.1 million (Q3 2012), $12.3 million (Q2 2012), and $8.8 million (Q1 2012), per Business Quant data.